Porocarcinoma (PC) is both uncommon and particularly challenging as a type of aggressive cancer that affects the eccrine sweat glands. At Protheragen, we offer a comprehensive suite of services dedicated to advancing the preclinical development of both diagnostics and therapeutics for porocarcinoma. Our integrated platform is designed to provide end-to-end support for our clients' research and development programs.
Overview of Porocarcinoma (PC)
Porocarcinoma (PC), or malignant eccrine poroma, is a skin cancer that is both rare and particularly aggressive. It develops from the intraepidermal ducts of eccrine sweat glands. This form of cancer is especially noteworthy for its aggressive metastatic spread towards regional lymph nodes and more distant organs, significantly complicating management. PC is diagnosed in the elderly, usually around the age of 70, and appears more often in the head, neck, and lower extremities. Its clinical picture, which often includes the formation of raised red (erythematous) nodules, ulceration, and bleeding, overlaps with the presentation of many other skin tumors, leading to misdiagnosis and late therapy initiation.
Fig.1 Histopathological findings of comedo necrosis. (Miyamoto K.,
et al., 2022)
Diagnostics Development for Porocarcinoma (PC)
Histopathology
Histological examination is a cornerstone in the diagnosis of PC. Characteristic features include mature duct formation, nuclear atypia, increased mitotic rate, and necrosis. However, these features can overlap with other cutaneous malignancies, making diagnosis challenging. For instance, a study by Robson et al. highlighted the histopathological diversity of PC, emphasizing the need for additional diagnostic tools to improve accuracy.
Immunohistochemistry
Immunohistochemical markers play a crucial role in differentiating PC from other tumors. Carcinoembryonic antigen (CEA) and epithelial membrane antigen (EMA) are frequently used markers, although their specificity is limited. More recently, the detection of YAP1 fusions through immunohistochemistry has shown high specificity for PC. For example, Sekine et al. demonstrated that YAP1-NUTM1 and YAP1-MAML2 fusions are highly specific for PC, providing a valuable diagnostic tool.
Dermoscopy
Dermoscopic examination can aid in the initial suspicion of PC by identifying polymorphic or atypical vessels, white globular structures, and milky-red globules. While these findings are not specific to PC, they can guide clinicians to pursue further histological confirmation. De Giorgi et al. described three distinct dermoscopic patterns in PC, emphasizing the importance of histological confirmation due to the nonspecific nature of these patterns.
Therapeutics Development for Porocarcinoma (PC)
- Chemotherapy: Systemic chemotherapy is used for metastatic or recurrent PC. Common agents include carboplatin, cisplatin, and 5-fluorouracil. Targeted therapies such as cetuximab (an EGFR inhibitor) have shown promise in some cases. For example, Godillot et al. reported a complete response in a patient treated with paclitaxel, cetuximab, and radiotherapy, demonstrating the potential of targeted therapies in PC.
- Immunotherapy: Immunotherapies like pembrolizumab (a PD-1 inhibitor) have demonstrated significant responses in a few reported cases, suggesting potential for further development. Lee et al. reported a case of metastatic PC achieving complete radiological and clinical response with pembrolizumab, highlighting the potential of immunotherapy in treating advanced PC.
Table 1. Therapeutics of Porocarcinoma (PC).
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Chemotherapy |
Carboplatin (CBDCA) |
DNA cross-linking inhibits DNA synthesis |
Commonly used in combination with other agents. |
Approved |
| Chemotherapy |
Cisplatin (CDDP) |
DNA cross-linking inhibits DNA synthesis |
Often used with 5-fluorouracil (5-FU). |
Approved |
| Chemotherapy |
5-Fluorouracil (5-FU) |
Inhibits thymidylate synthase, disrupts DNA synthesis |
Used in combination with cisplatin. |
Approved |
| Chemotherapy |
Docetaxel (DTX) |
Inhibits microtubule depolymerization, induces cell cycle arrest |
Used in combination with other chemotherapy agents. |
Approved |
| Chemotherapy |
Paclitaxel (PTX) |
Inhibits microtubule depolymerization, induces cell cycle arrest |
Used in combination with other chemotherapy agents. |
Approved |
| Targeted Therapy |
Cetuximab |
Monoclonal antibody targeting EGFR |
Inhibits EGFR signaling, reduces cell proliferation. |
Approved |
| Immunotherapy |
Pembrolizumab |
PD-1 inhibitor |
Enhances T-cell activity against cancer cells. |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Protheragen offers a comprehensive range of services dedicated to the advancement of PC diagnostics and therapeutics. From preclinical research and drug development to customized solutions and diagnostic assay design, our team is equipped to support every stage of the PC research and development pipeline. With a focus on scientific excellence, technical innovation, and client satisfaction, Protheragen is your trusted partner in the fight against Porocarcinoma.
Disease Models
- N-Nitrosobis(2-oxopropyl) amine (BOP)-Induced Models
- 7,12-Dimethylbenz(a)anthracene (DMBA)-Induced Models
- Patient-Derived Tumor Xenograft (PDX) Models
Protheragen's competitive advantage lies in our ability to integrate cutting-edge science with practical business acumen. We understand the challenges and opportunities inherent in the PC diagnostics and therapeutics landscape and are dedicated to providing our clients with solutions that are not only scientifically sound but also commercially viable. If you are interested in our services, please feel free to contact us.
References
- Miyamoto, Kodai, et al. "Diagnosis and management of porocarcinoma." Cancers 14.21 (2022): 5232.
- Bienstman, Thomas, Canan Güvenç, and Marjan Garmyn. "Porocarcinoma: clinical and histological features, immunohistochemistry and outcomes: a systematic review." International journal of molecular sciences 25.11 (2024): 5760.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
